MedWatch

Orphazyme down to 20 employees after multiple firing rounds

Biotech company Orphazyme has cut staff numbers to around 20, down from 180 last summer, according to Deputy Chair Bo Jesper Hansen.

The negative events of the past year involving Orphazyme have not just made their mark on the biotech company’s finances, but also on its number of staff.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs